Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Arry Harryanto Reksodiputro"'
Publikováno v:
Jurnal Penyakit Dalam Indonesia, Vol 5, Iss 3, Pp 146-149 (2018)
Composite lymphoma (CL) is a rare disease. Composite lymphoma is two or more different type of lymphoma that sequentially or simultaneously occur in one anatomical site. Making a diagnosis of CL is a challenge and there is still no guidelines about t
Externí odkaz:
https://doaj.org/article/c3ec3806fd07439491ee4302c6ae23c4
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Supplementary Methods, Supplementary Figure Legends, Supplementary Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0494cbfb70206985634a6c110a3bed99
https://doi.org/10.1158/1078-0432.22466123.v1
https://doi.org/10.1158/1078-0432.22466123.v1
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Kaplan-Meier estimated progression-free survival (PFS) in the intention-to-treat population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03a5ba45cac3052fa7019dc560fa4fba
https://doi.org/10.1158/1078-0432.22466129
https://doi.org/10.1158/1078-0432.22466129
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Major molecular response by 12 months, by Sokal risk group. bid, twice daily; MMR, major molecular response (defined as BCR-ABL1 transcript level {less than or equal to}0.1% [MR3.0]); qd, daily.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3efd1db8b4ec98559ea8fcd928730fb1
https://doi.org/10.1158/1078-0432.22466132.v1
https://doi.org/10.1158/1078-0432.22466132.v1
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9374f34c079b8a9da3ff6c858e2b66a3
https://doi.org/10.1158/1078-0432.c.6526247
https://doi.org/10.1158/1078-0432.c.6526247
Autor:
Dong-Wook Kim, Sung-Eun Lee, Priscilla B. Caguioa, Arry Harryanto Reksodiputro, Saengsuree Jootar, Narcisa Sonia Comia, Udomsak Bunworasate, Chul Won Jung, Jinny Park, Dae-Young Kim, Ho-Jin Shin, Joo Seop Chung, Jee Hyun Kong, Yeung-Chul Mun, Won Sik Lee, Chul Won Choi, Joon Seong Park, Hyeoung Joon Kim, Young Rok Do, Jeong-A Kim, Hawk Kim, Dae Young Zang, Suk Joong Oh, Sung-Hyun Kim, Jae-Yong Kwak
Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (c) Radotinib 300 mg bid (n = 79 patients with evaluable molecular data at 3 months).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea270c05ca497a09533ec742014d7bc
https://doi.org/10.1158/1078-0432.22466135
https://doi.org/10.1158/1078-0432.22466135
Autor:
Young Rok Do, Hyeoung Joon Kim, Arry Harryanto Reksodiputro, Dae-Young Kim, Jee Hyun Kong, Saengsuree Jootar, Ho Jin Shin, Joo Seop Chung, Narcisa Sonia Cornejo Comia, Jae Yong Kwak, Sukjoong Oh, Dae Young Zang, Priscilla B. Caguioa, Sung-Hyun Kim, Dong-Wook Kim, Udomsak Bunworasate, Won Sik Lee, Yeung-Chul Mun, Chul Won Choi, Chul Won Jung, Hawk Kim, Joon Seong Park, Sung-Eun Lee, Jeong-A Kim, Jinny Park
Publikováno v:
Clinical Cancer Research. 23:7180-7188
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2179ddc57f07ae4d02707cef173ddef2
https://doi.org/10.1158/1078-0432.ccr-17-0957
https://doi.org/10.1158/1078-0432.ccr-17-0957
Publikováno v:
Jurnal Penyakit Dalam Indonesia. 5:146
Limfoma komposit merupakan penyakit yang jarang terjadi. Limfoma komposit merupakan dua atau lebih tipe limfoma berbeda yang terjadi pada satu lokasi anatomi, baik secara bersamaan maupun sekuensial. Proses diagnostik limfoma komposit memiliki tantan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcac1df59c35a76161ba1a2fdf895d0a
https://doi.org/10.7454/jpdi.v5i3.200
https://doi.org/10.7454/jpdi.v5i3.200